Contrezin 0,03 mg, 3,0 mg Tablet
PDF Leaflet Revision Date: 02/09/2025
Clinical Summary
Quick overview from the medicine insert
Indication
Oral contraception.
Dosage (summary)
One tablet daily for 28 days, starting on day 1 of the menstrual cycle.
Special Populations
- Paediatric population
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not indicated during pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Enzyme inducers (e.g., phenytoin, rifampicin)
- Strong CYP3A4 inhibitors (e.g., ketoconazole)
- Antibiotics (e.g., penicillins, tetracyclines)
Contraindications
- Hypersensitivity to components
- Venous thromboembolism
- Arterial thromboembolism
- Severe hepatic disease
- Severe renal insufficiency
- Liver tumors
- Undiagnosed vaginal bleeding
- Pregnancy
Common side effects
- Nausea
- Headache
- Depressive mood
- Breast tenderness
- Weight changes
Counselling Points
- Take at the same time daily
- Use barrier method if tablets missed
- Report any mood changes or thromboembolic symptoms
Serious warnings
- Increased risk of VTE and ATE
- Monitor for hypertension
- May influence insulin resistance
Important Disclaimer
The Contrezin 0,03 mg, 3,0 mg Tablet professional information leaflet below is the property of Innovata Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
